Various non-injectable delivery systems for the treatment of diabetes mellitus

• Author

Language of Original Document: English
Correspondence Address: Adams, G.G.; Insulin and Diabetes Experimental Research Group, University of Nottingham, Faculty of Medicine and Health Science, Clifton Boulevard, Nottingham NG7 2RD, United Kingdom; email: Gary.Adams@nottingham.ac.uk
Chemicals/CAS: insulin, 9004-10-8; Aerosols; Capsules; Hydrogels; Insulin, 11061-68-0
Tradenames: Aerodose, Aerogen, United States; AERx, Aradigm, United States; AIR, Alkermes, United States; AIR, Lilly, United States; Exebura, Nektar, United States; Technospere, MannKind, United States
Manufacturers: Aerogen, United States; Alkermes, United States; Aradigm, United States; Lilly, United States; MannKind, United States; Nektar, United States
References: http://www.who.int/diabetes/en/ last accessed on 2008-01-28Diabetes Atlas, 3rd ed. © International Diabetes Federation, 2006Williams, R., Airey, M., Baxter, H., Forrester, J., Kennedy-Martin, T., Girach, A., Epidemiology of diabetic retinopathy and macular oedema: A systematic review (2004) Eye, 18 (10), pp. 963-983; Tesch, G.H., Nikolic-Paterson, D.J., Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice (2006) Nephron. Exp. Nephrol, 104 (2), pp. e57-e62; Evans, M.J., Kaufman, M.H., Establishment in culture of pluripotential cells from mouse embryos (1981) Nature, 292 (5819), pp. 154-156; Somers, E.C., Thomas, S.L., Smeeth, L., Hall, A.J., Autoimmune diseases co-occurring within individuals and within families: A systematic review (2004) Epidemiology, 17 (2), pp. 202-217; Steil, G.M., Panteleon, A.E., Rebrin, K., Closed-loop insulin delivery - the path to physiological glucose control (2004) Adv. Drug Deliv. Rev, 56 (2), pp. 125-144; Varshosaz, J., Insulin delivery systems for controlling diabetes (2007) Recent Patents Endocrine, Metab. Immun. Drug Discov, 16 (1), pp. 25-40; Silvaa, C., Ribeirob, A.J., Ferreirac, D., Veigaa, F., Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation (2006) Eur. J. Pharm. Sci, 29 (2), pp. 148-159; Barichello, J.M., Morishita, M., Takayama, K., Chiba, Y., Tokiwa, S., Nagai, T., Enhanced rectal absorption of insulin-loaded Pluronic® F-127 gels containing unsaturated fatty acids (1999) Int. J. Pharm, 183 (2), pp. 125-132; Owens, D.R., Zinman, B., Bolli, G., Alternative routes of insulin delivery (2003) Diabet. Med, 20 (11), pp. 886-898; Narayani, R., Artificial cell therapy: New strategies for the therapeutic delivery of live bacteria (2001) Trends Biomater. Artifi. Organs, 15 (1), pp. 12-16; Lee, Y.C., Simamora, P., Yalkowsky, S.H., Systemic delivery of insulin via an enhancer-free ocular device (1997) J. Pharm. Sci, 86 (12), pp. 1361-1364; Chiou, G.C.Y., Effect of formulation on the systemic absorption of insulin from enhancer-free ocular devices (1991) Annu. Rev. Pharmacol, 31 (1), pp. 457-467; Lee, Y.C., Simamora, P., Yalkowsky, S.H., Effect of Brij-78 on systemic delivery of insulin from an ocular device (1997) J. Pharm. Sci, 86 (4), pp. 430-433; Jabbal-Gill, I., Fisher, A.N., Rappuoli, R., Davis, S.S., Illum, L., Vaccination of rock bream, Oplegnathus fasciatus (Temminck & Schlegel), using a recombinant major capsid protein of fish iridovirus (1998) Vaccine, 16 (20), pp. 2039-2046; Cernea, S., Raz, I., Intranasal insulin: PK profile designed specifically for prandial treatment of Type 2 Diabetes (2006) Drugs Today, 42 (6), pp. 405-424; Gizurarson, S., Bechgaard, E., Intranasal administration of insulin to humans (1991) Diabetes Res. Clin. Pract, 12 (2), pp. 71-84; Turker, S., Onur, E., Ozer, Y., Pharmaceutical significance of chitosan: A review (2004) Pharm. World Sci, 26 (3), pp. 137-142; Drejer, K., Vaag, A., Bech, K., Hansen, P., Sorensen, A.R., Mygind, N., Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin (1992) Diabet. Med, 9 (4), pp. 335-340; Jacobs, M.A., Schreuder, R.H., Jap-A-Joe, K., Nauta, J.J., Andersen, P.M., Heine, R.J., The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers (1993) Diabetes, 42 (11), pp. 1649-1655; Moses, A.C., Gordon, G.S., Carey, M.C., Flier, J.S., Nasal absorption of insulin: Enhancement by hydrophobic bile salts (1983) Diabetes, 32 (11), pp. 1040-1047; Nolte, M.S., Taboga, C., Salamon, E., Moses, A., Longenecker, J., Flier, J., Karam, J.H., Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer (1990) Hormone Metab. Res, 22 (3), pp. 170-174; Bruce, D.G., Chisholm, D.J., Storlien, L.H., Borkman, M., Kraegen, E.W., Meal-time intranasal insulin delivery in Type 2 diabetes (1991) Diabet. Med, 8 (4), pp. 366-370; Liu, L., Fishman, M.L., Hicks, K.B., Pectin in controlled drug delivery - a review (2007) Cellulose, 14 (1), pp. 15-24; Liu, L., Fishman, M.L., Kost, J., Hicks, K.B., Pectin-based systems for colon-specific drug delivery via oral route (2003) Biomaterials, 24 (19), pp. 3333-3343; Cernea, S., Kidron, M., Wohlgelernter, J., Modi, P., Raz, I., Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycaemic clamp technique (2004) Clin. Ther, 26 (12), pp. 2084-2091; Modi, P., Mihic, M., Lewin, A., The evolving role of oral insulin in the treatment of diabetes using a novel RapidMistSystem (2002) Diab. Metab. Res. Rev, 18 (1), pp. S38-S42; Lin, Y.H., Chen, C.H., Liang, H.F., Kulkarni, A.R., Lee, P.W., Chen, C.H., Sung, H.W., Novel nanoparticles for oral insulin delivery via the paracellular pathway (2007) Nanotechnology, 18 (10), pp. 1-11; Carino, G.P., Jacob, J.S., Mathiowitz, E., Nanosphere based oral insulin delivery (2000) J. Control. Rel, 65 (1-2), pp. 261-269; Mesiha, M., Plakogiannis, F., Vejosoth, S., Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: Ex vivo and in vivo studies (1994) Int. J. Pharm, 111 (3), pp. 213-216; Yamamoto, A., Taniguchi, T., Rikyuu, K., Tsuji, T., Fujita, T., Murakami, M., Muranishi, S., Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats (1994) Pharm. Res, 11 (10), pp. 1496-1500; Morishita, I., Morishita, M., Takayama, K., Machida, Y., Nagai, T., Enteral insulin delivery by microspheres in 3 different formulations using Eudragit® L100 and S100 (1993) Int. J. Pharm, 91 (1), pp. 29-37; Sarmento, B., Ribeiro, A., Veiga, F., Ferreira, D., Neufeld, R., Oral bioavailability of insulin contained in polysaccharide nanoparticles (2007) Biomacromolecules, 8 (10), pp. 3054-3060; Jain, D., Panda, A.K., Majumdar, D.K., Eudragit S100 entrapped insulin microspheres for oral delivery (2005) AAPS Pharm. Sci. Tech, 6 (1), pp. E100-E107; Gaensslen, M., Ueber Inhalation von Insulin. (1925) Klin. Wochenschr, 4 (2), p. 71; Banting, F.G., Best, C.H., Macleod, J.J.R., The internal secretion of the pancreas (1922) Am. J. Physiol, 59 (1), p. 479; Cernea, S., Kidron, M., Wohlgelernter, J., Modi, P., Raz, I., Dose-response relationship of oral insulin spray in healthy subjects (2005) Diabetes Care, 28 (6), pp. 1353-1357; Mygind, N., Treating Diabetes With Aerosolized Insulin: In Aerosols in medicine (1985) Principles, diagnosis and therapy, pp. 1-20. , Moren, F, Newhouse, M.T. and Dolovich, M. B. Eds, New York, Elsevier Science Publishers; Byron, P.R., Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation (1986) J. Pharm. Sci, 75 (5), pp. 433-438; Gil, J., Number and distribution of plasmalemmal vesicles in the lung (1983) Fed. Proc, 42 (8), pp. 2414-2418; Jendle, J.H., Karlberg, B.E., Intrapulmonary insulin administration in healthy volunteers (1996) J. Int. Med, 240 (2), pp. 93-98; Galloway, J.A., Spradlin, C.T., Nelson, R.L., Wnetworth, S.M., Davidson, J.A., Swarner, J.L., Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures (1981) Diabetes Care, 4 (3), pp. 366-376; Patton, J., Pulmonary delivery of insulin (2006) Curr. Med. Res. Opin, 22 (3), pp. S5-S11; Scheuch, G., Siekmeier, R., Novel approaches to enhance pulmonary delivery of proteins and peptides (2007) J. Physiol. Pharmacol, 58 (5), pp. 615-625; Agu, R.U., Ugwoke, M.I., Armand, M., Kinget, R., Verbeke, N., The lung as a route for systemic delivery of therapeutic proteins and peptides (2001) Respir. Res, 2 (4), pp. 198-209; Niven, R.W., Delivery of biotherapeutics by inhalation aerosol (1995) Crit. Rev. Ther. Drug Carrier Syst, 12 (2-3), pp. 151-231; Deshpande, D., Blanchard, J., Srinivasan, S., Fairbanks, D., Fujimoto, J., Sawa, T., Wiener-Kronish, J., Gonda, I., Aerosolization of lipoplexes using AERx® pulmonary delivery system (2002) AAPS Pharm. Sci, 4 (3), pp. 1-10; Mandal, T.K., Inhaled insulin for diabetes mellitus (2005) Am. J. Health-Syst. Pharm, 62 (13), pp. 1359-1364; Laube, B.L., Treating diabetes with aerosolised insulin (2001) Chest, 120 (3), pp. 99S-106; Crowder, T.M., Louey, M.D., Sethuraman, V.V., Smyth, H.D.C., Hickey, A., An odyssey in inhaler formulations and design (2001) J. Pharm. Tech, 25 (7), pp. 99-113; Laube, B.L., Benedict, W., Dobs, A.S., Time to peak insulin level, relative bioavailability and effect of site of deposition of nebulized insulin in patients with non-insulin-dependent diabetes mellitus (1998) J. Aerosol. Med, 11 (3), pp. 153-173; Elliott, R.B., Edgar, B.W., Pilcher, C.C., Quested, C., McMaster, J., (1987) Aust. Paediatr. J, 23 (5), pp. 293-297; Selam, J.L., Inhaled insulin for the treatment of diabetes: Projects and devices (2003) Exp. Opin. Pharmacol, 4 (8), pp. 1373-1377; Mumenthaler, M., Hsu, C.C., Pearlman, R., Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator (1994) Pharm. Res, 11 (1), pp. 12-20; Heinemann, L., Pfutzner, A., Heise, T., Alternative routes of administration as an approach to improve insulin therapy: Update on dermal, oral, nasal and pulmonary insulin delivery (2001) Curr. Pharm. Des, 7 (14), pp. 1327-1351; Schultz, H., Mechanisms and factors affecting intrapulmonary particle deposition: Implications for efficient inhalation therapies (1998) Pharmaceut. Sci. Technol, 1 (8), pp. 336-344; Farr, S.J., McElduff, A., Mather, L.E., Okikawa, J., Ward, M.E., Gonda, I., Vojtech, L., Rubsamen, R.M., Pulmonary insulin administrationusing the AERx™ system: Physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects (2000) Diabetes Technol. Therapeut, 2 (2), pp. 185-197; Brådvik, I., Wollmer, P., Evander, E., Sloth, M., Lárusdóttir, H., Blom-Bülow, B., Jonson, B., One year follow-up of lung clearance of 99mTc-diethylene traimine penta-acetic acid and diseases activity in sarcodisis (2000) Vasculitis Diffuse Lung Dis, 17 (3), pp. 281-287; Wollmer, P., Evander, E., Biphasic pulmonary clearance of 99mTc-DPTA in smokers (1994) Clin. Physiol, 14 (5), pp. 547-559; Minty, B.D., Royston, D., Jones, J.G., Hulands, G.H., The effect of nicotine on pulmonary epithelial permeability in man (1984) Chest, 86 (1), pp. 72-74; Meignan, M., Rosso, J., Leveau, J., Katz, A., Cinotti, L., Madelaine, G., Galle, P., Exercise increases the lung clearance of inhaled technetium-99m DPTA (1986) J. Nucl. Med, 27 (2), pp. 274-280; Schmekel, B., Borgstrom, L., Wollmer, P., Exercise increases the rate of pulmonary absorption of inhaled terbulatie (1992) Chest, 101 (3), pp. 742-745; Fink, J.B., Metered-dose inhalers, dry powder inhalers, and transitions (2000) Resp. Care, 456 (6), pp. 623-635; Kubelka, J., Huang, R., Keiderling, T.A., Solvent effects on ir and vcd spectra of helical peptides: Dft-based static spectral simulations with explicit water (2005) J. Phys. Chem. B, 109 (16), pp. 8231-8243; Laube, B.L., Georgopoulos, A., Adams 3rd, G.K., Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients (1993) JAMA, 69 (16), pp. 2106-2109; Maa, Y.F., Prestrelski, S.J., Biopharmaceutical powders particle formation and formulation considerations (2000) Curr. Pharm. Biotech, 1 (3), pp. 283-302; Tyagi, P., Insulin delivery systems: Present trends and the future direction (2002) Ind. J. Pharmacol, 34 (6), pp. 379-389; Thompson, P.J., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (1998) Am. J. Respir. Crit. Care Med, 157 (5), pp. 199-202; Keller, M. and Müller-Walz, R. (2000) Development of dry powder inhalers WO0028979Chougule, M.B., Padhi, B.K., Jinturkar, K.A., Misra, A., Development of dry powder inhalers (2007) Recent Patents Drug Deliv. Formulat, 1 (1), pp. 11-21; Edwards, D.A., Ben-Jerbria, A., Langer, R., Recent advances in pulmonary drug delivery using large, porous inhaled particles (1998) J. Appl. Physiol, 85 (2), pp. 379-385; Rosenstock, J., Mealtime rapid acting inhaled insulin (Exubera®) improves glycaemic control in patients with type 2 diabetes failing combination oral agents: A 3 month randomised comparative trial (2002) Diabetes, 51 (2), pp. A132-A133; Belanger, A., Efficacy and safety of inhaled insulin (Exubera®) compared to sc insulin therapy in patients with type 2 diabetes. Results of a 6 month randomised comparative trial (2002) Diabetologia, 45 (2), pp. A260; Henry, R.R., Mudaliar, S.R., Howland III, W.C., Chu, N., Kim, D., An, B., Reinhardt, R.R., Pulmonary delivery of insulin using the AERx™ insulin diabetes management system in healthy and asthmatic subjects (2003) Diabetes Care, 26 (3), pp. 764-769; Skyler, J.S., Weinstock, R.S., Raskin, P., Yale, J.F., Barrett, E., Gerich, J.E., Gerstein, H.C., Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects A 6-month, randomized, comparative trial (2005) Diabetes Care, 28 (7), pp. 1630-1635; DeFronzo, R.A., Bergenstal, R.M., Cefalu, W.T., Pullman, J., Lerman, S., Bode, B.W., Phillips, L.S., Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial (2005) Diabetes Care, 28 (8), pp. 1922-1928; Weiss, S.R., Cheng, S.L., Kourides, I.A., Gelfand, R.A., Landschulz, W.H., The Inhaled Insulin Phase II Study Group: Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial (2003) Arch. Intern. Med, 163 (19), pp. 2277-2282; Cefalu, W.T., Balagtas, C.C., Landshultz, W.H., Gelfand, R.A., Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy (2000) Diabetologia, 43 (1), pp. A47; Staniforth, J.N. (1995) Development of dry powder inhalers WO9511666Trofast, J. (1998) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising Formoterol WO9831351Edwards, D.A., Caponetti, G.H., Jeffrey, S., Lotan, N., Hanes, J., Ben-Jebria, A., Langer, R.S., Development of dry powder inhalers (2000), US20006399102Edwards, D.A., Caponetti, G.H., Jeffrey, S., Lotan, N., Hanes, J., Ben-Jebria, A., Langer, R.S., Development of dry powder inhalers (2005), US20050244341Hodson, P.D., Smith, D.K., Velasquez, D.J., Wass, A.C.L., Calhoun, C.D., Development of dry powder inhalers (1998), US5740793Jahr, H., Bretzel, B., Insulin-positive cells in vitro generated from rat bone marrow stromal cells (2003) Transplant. Proc, 35 (6), pp. 2140-2141; Ianus, A., Holz, G.G., Theise, N.D., Hussain, M.A., In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion (2003) J. Clin. Invest, 111 (6), pp. 843-850; Newgard, C.B., An artificial beta cell produced by engineering endocrine cells of the At-T-20 ACTH secreting cells (2005), US5427940Laurance, M.E., Knaack, D., Fiore, D.M., Hegre, O.D., Glucose responsive insulin secreting beta-cell lines (1996), US5534404Stock, P.G., Bluestone, J.A., Beta-cell replacement for type I diabetes (2004) Ann. Rev. Med, 55 (1), pp. 133-156; Tanaka, T., Fillmore, D., Sun, S., Nishio, I., Swislow, G., Shah, A., Phase transitions in ionic gels (1980) Phys. Rev. Lett, 45 (20), pp. 1636-1639; Hoffman, J., Plotner, M., Kuc